Becton, Dickinson and Company (NYSE:BDX) Receives $196.00 Consensus Price Target from Brokerages

Shares of Becton, Dickinson and Company (NYSE:BDX) have received a consensus recommendation of “Hold” from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $195.4615.

Several equities research analysts recently issued reports on BDX shares. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Jefferies Financial Group dropped their price objective on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Wells Fargo & Company lowered their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 10th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $170.00 price target (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,610 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 2,463 shares of company stock valued at $501,530 in the last ninety days. Insiders own 0.40% of the company’s stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several hedge funds have recently bought and sold shares of BDX. Arete Wealth Advisors LLC raised its holdings in Becton, Dickinson and Company by 9.1% in the 4th quarter. Arete Wealth Advisors LLC now owns 4,857 shares of the medical instruments supplier’s stock worth $943,000 after acquiring an additional 405 shares during the last quarter. Jacobi Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 11.0% in the 4th quarter. Jacobi Capital Management LLC now owns 8,711 shares of the medical instruments supplier’s stock valued at $1,691,000 after purchasing an additional 865 shares during the last quarter. Kestra Advisory Services LLC grew its holdings in Becton, Dickinson and Company by 4.9% during the 4th quarter. Kestra Advisory Services LLC now owns 14,627 shares of the medical instruments supplier’s stock valued at $2,839,000 after purchasing an additional 681 shares during the last quarter. Transamerica Financial Advisors LLC boosted its position in Becton, Dickinson and Company by 15.3% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,435 shares of the medical instruments supplier’s stock valued at $278,000 after buying an additional 190 shares during the period. Finally, UMB Bank n.a. raised its holdings in shares of Becton, Dickinson and Company by 6.5% in the 4th quarter. UMB Bank n.a. now owns 6,932 shares of the medical instruments supplier’s stock valued at $1,345,000 after purchasing an additional 422 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.0%

NYSE:BDX opened at $175.95 on Thursday. The firm has a market capitalization of $50.10 billion, a price-to-earnings ratio of 28.70, a PEG ratio of 2.30 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $185.02. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $198.82 and its two-hundred day moving average price is $192.26.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company declared that its board has approved a stock buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Citi raised its price target after a life‑sciences sale update, signaling potential value support if BDx proceeds with portfolio moves. Citi raises Becton Dickinson PT to $198
• Positive Sentiment: Jefferies issued a buy, supporting the view that BDx’s portfolio reshaping and product investments can sustain growth. Becton Dickinson Gets a Buy from Jefferies
• Positive Sentiment: TD Cowen nudged its target higher to $189 (hold), reflecting modest upside from current levels and adding another analyst vote of confidence. TD Cowen adjusts Becton Dickinson PT to $189
• Neutral Sentiment: Company Q4 review: management says portfolio reshaping and product investments offset tariff headwinds — useful context for earnings quality but not an immediate directional catalyst. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Negative Sentiment: Zacks Research cut BDX from “hold” to “strong sell,” a notable downgrade that likely pressured sentiment and contributed to the share weakness. Zacks Research downgrade
• Negative Sentiment: AmericanBankingNews reports Citigroup lowered a prior target (headline shows a cut to $232), adding further mixed signals from the sell‑side. Citigroup Lowers Becton Dickinson PT to $232
• Negative Sentiment: JPMorgan and Wells Fargo issued pessimistic forecasts in separate notes, increasing analyst pressure and downside risk in the near term. JPMorgan pessimistic forecast Wells Fargo pessimistic forecast
• Negative Sentiment: Coverage flow drove a gap‑down headline after the analyst activity, reflecting short‑term selling pressure from downgrades and mixed guidance expectations. Shares gap down on analyst downgrade

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.